Company aims at strong growth in 2018 – Mid-term targets through 2020 confirmed – Growth initiatives for the next decade put in place

If no timeframe is specified, information refers to fiscal year 2017.

Fiscal year 2017:

  • Sales €33.9 billion (+15%, +16% in constant currency)
  • EBIT1 (adjusted) €4,890 million (+14%, +15% in constant currency)
  • Net income2,3 (adjusted) €1,859 million (+19%, +21% in constant currency)
  • Net income3 (before special items) €1,816 million (+16%, +18% in constant currency)
  • Net income3 €1,814 million (+16%, +18% in constant currency)
  • Dividend proposal €0.75 per share (+21%)

Q4/2017:

  • Sales €8.7 billion (+11%, +17% in constant currency)
  • EBIT1 (adjusted) €1,354 million (+9%, +14% in constant currency)
  • Net income2,3 (adjusted) €520 million (+18%, +22% in constant currency)
  • Net income3 (before special items) €487 million (+10%, +15% in constant currency)
  • Net income3 €511 million (+16%, +21% in constant currency)

1 Before acquisition-related expenses, expenditures for further development of biosimilars business and FCPA provision
2 Consistent with scope of original guidance: before acquisition-related expenses, expenditures for further development of biosimilars business, book gain from U.S. tax reform and FCPA provision
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Stephan Sturm, CEO of Fresenius, said: “At Fresenius, 2017 was a year of tremendous accomplishments. Our dedicated doctors and nurses treated 17 million patients in our hospitals – and helped bring over 70,000 babies into the world. Over 320,000 dialysis patients received more than 48 million life-saving treatments in our clinics. And healthcare systems benefited as we launched over 90 new generic – and therefore less expensive – drugs. All of this was achieved by the more than 270,000 people whom it was our privilege to employ last year. Our business results reflect our successful work for people. Record sales and earnings in 2017, along with the company’s strong guidance for this year and through 2020, show that our uncompromising focus on patients and quality also pays for our investors.”

Investigation into alleged breaches of FDA data integrity requirements at Akorn, Inc.

Fresenius is conducting an independent investigation, using external experts, into alleged breaches of FDA data integrity requirements relating to product development at Akorn, Inc. The Management and Supervisory Boards of Fresenius will assess the findings of that investigation. The consummation of the transaction may be affected if the closing conditions under the merger agreement are not met. Fresenius does not intend to provide further updates as the investigation proceeds. Fresenius continues to seek FTC clearance.

Strong Group guidance1 for 2018
For 2018, Fresenius projects sales growth2 of 5% to 8% in constant currency. Net income3,4 is expected to grow by 6% to 9% in constant currency. Excluding expenditures for the further development of the biosimilars business, net income3,5 is expected to grow by ~10% to 13% in constant currency.

Fresenius expects to further reduce its net debt/EBITDA6 ratio by year-end 2018.

Mid-term growth targets 2020 confirmed7
Based on the strong financial results 2017, Fresenius confirms the 2020 mid-term growth targets. Group sales are expected to grow with a compounded annual growth rate (CAGR) in the range of 7.1% to 10.3% (Mid-point: 8.7%). Group net income3 is projected to increase with a CAGR in the range of 8.3% to 12.6% (Mid-point: 10.5%).

25th consecutive dividend increase proposed
Based on the strong financial results, the Management Board will propose to the Supervisory Board a dividend increase of 21% to €0.75 per share (2016: €0.62). The expected dividend distribution to the shareholders of Fresenius SE & Co. KGaA is €416 million.

1 Excluding pending acquisitions of Akorn and NxStage
2 2017 adjusted for IFRS 15 (€486 million at Fresenius Medical Care)
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
4 Base 2017: €1,816 million; 2018 before special items (before acquisition-related expenses); including expenditures for further development of biosimilars business (€43 million after tax in FY/17 and ~€120 million after tax in FY/18)
5 Base 2017: €1,859 million; 2018 before special items (before acquisition-related expenses)
6 Calculated at expected annual average exchange rates, for both net debt and EBITDA; excluding pending acquisitions of Akorn and NxStage; excluding further potential acquisitions; at current IFRS rules
7 At February 2017 exchange rates and IFRS rules; including small and mid-size acquisitions


16% sales growth in constant currency
Group sales increased by 15% (16% in constant currency) to €33,886 million (2016: €29,471 million). Organic sales growth was 6%. Acquisitions contributed 10%. Negative currency translation effects (1%) were mainly driven by the devaluation of the US dollar and the Chinese yuan against the euro. In Q4/2017, Group sales increased by 11% (17% in constant currency) to €8,695 million (Q4/2016: €7,820 million). Organic sales growth was 6%. Acquisitions contributed 11%.

Group sales by region:

1 Calculated on the basis of contribution to consolidated sales
2 Including effects of agreement with the U.S. Departments of Veterans Affairs and Justice (VA agreement)


21% adjusted net income1,2 growth in constant currency

Group EBITDA3 increased by 14% (15% in constant currency) to €6,267 million (2016: €5,517 million). Adjusted Group EBIT4 increased by 14% (15% in constant currency) to €4,890 million (2016: €4,302 million). The adjusted EBIT margin4 was 14.4% (2016: 14.6%). In Q4/2017, adjusted Group EBIT4 increased by 9% (14% in constant currency) to €1,354 million (Q4/2016: €1,244 million), the adjusted EBIT margin4 was 15.6% (Q4/2016: 15.9%). Group EBIT3 before special items increased by 12% (14% in constant currency) to €4,830 million (2016: €4,302 million). The EBIT margin3 was 14.3% (2016: 14.6%). In Q4/2017, Group EBIT3 increased by 5% (11% in constant currency) to €1,308 million (Q4/2016: €1,244 million), the EBIT margin3 was 15.0% (Q4/2016: 15.9%).

Group net interest3 reached -€636 million (2016: -€582 million). The increase is mainly driven by the financing of the Quirónsalud acquisition, partly offset by positive effects from refinancing activities.

The Group tax rate before special items was 28.2% (2016: 28.1%). The U.S. tax reform, which went into effect on January 1, 2018, triggered a revaluation of deferred tax liabilities. This resulted in a one-time book gain of €103 million in 2017. Accordingly, the group tax rate after special items decreased to 23.0%.

Noncontrolling interest3 was €1,194 million (2016: €1,116 million), of which 95% was attributable to the noncontrolling interest in Fresenius Medical Care.

Adjusted Group net income1,2 increased by 19% (21% in constant currency) to €1,859 million (2016: €1,560 million). Adjusted earnings per share1,2 increased by 18% (19% in constant currency) to €3.35 (2016: €2.85). In Q4/2017, adjusted Group net income1,2 increased by 18% (22% in constant currency) to €520 million (Q4/2016: €442 million). Adjusted earnings per share1,2 increased by 16% (20% in constant currency) to €0.93 (Q4/2016: €0.81).

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
2 Consistent with scope of original guidance: before acquisition-related expenses, expenditures for further development of biosimilars business, book gain from U.S. tax reform and FCPA provision
3 Before special items
4 Consistent with scope of original guidance: before acquisition-related expenses, expenditures for further development of biosimilars business and FCPA provision

For a detailed overview of special items and adjustments please see the reconciliation tables on pages 18-19 in the pdf document.

Group net income before special items1 increased by 16% (18% in constant currency) to €1,816 million (2016: €1,560 million). Earnings per share1,2 increased by 15% (16% in constant currency) to €3.28 (2016: €2.85). In Q4/2017, Group net income1,2 increased by 10% (15% in constant currency) to €487 million (Q4/2016: €442 million). Earnings per share1,2 increased by 9% (13% in constant currency) to €0.88 (Q4/2016: €0.81).

Group net income1 increased by 16% (18% in constant currency) to €1,814 million
(2016: €1,560 million). Earnings per share1 increased by 15% (16% in constant currency) to €3.27 (2016: €2.85). In Q4/2017, Group net income1 increased by 16% (21% in constant currency) to €511 million (Q4/2016: €442 million). Earnings per share1 increased by 14% (19% in constant currency) to €0.92 (Q4/2016: €0.81).

Continued investment in growth
Spending on property, plant and equipment was €1,828 million (2016: €1,633 million), primarily for the modernization and expansion of dialysis clinics, production facilities as well as hospitals and day clinics. This corresponds to 5.4% of sales.

Total acquisition spending of €6,852 million (2016: €926 million) was mainly related to the acquisitions of Quirónsalud and Merck KGaA’s biosimilars business.

Excellent cash flow development
Operating cash flow increased by 10% to €3,937 million (2016: €3,585 million) with a margin of 11.6% (2016: 12.2%). The excellent cash flow was driven by Fresenius Medical Care and a record cash flow at Fresenius Kabi.

Free cash flow before acquisitions and dividends increased by 13% to €2,232 million (2016: €1,969 million), with a margin of 6.6% (2016: 6.7%). Free cash flow after acquisitions and dividends was €-4,557 million (2016: €746 million) reflecting the acquisitions of Quirónsalud and Merck KGaA’s biosimilars business.

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
2 Before special items


Solid balance sheet structure
The Group’s total assets increased by 14% (21% in constant currency) to €53,133 million (Dec. 31, 2016: €46,697 million), driven primarily by the acquisition of Quirónsalud. Current assets grew by 7% (15% in constant currency) to €12,604 million (Dec. 31, 2016: €11,744 million). Non-current assets increased by 16% (23% in constant currency) to €40,529 million (Dec. 31, 2016: € 34,953 million).

Total shareholders’ equity increased by 4% (14% in constant currency) to €21,720 million (Dec. 31, 2016: €20,849 million). The equity ratio decreased to 40.9% (Dec. 31, 2016: 44.6%).

Group debt increased by 29% (35% in constant currency) to €19,042 million (Dec. 31, 2016: € 14,780 million), mainly driven by the acquisition financing of Quirónsalud. Group net debt increased by 32% (37% in constant currency) to € 17,406 million (Dec. 31, 2016: € 13,201 million.

As of December 31, 2017, the net debt/EBITDA ratio was 2.841,2 (September 30, 2017: 2.971,2; December 31, 2016: 2.331; pro forma Quirónsalud 3.091).

1 At LTM average exchange rates for both net debt and EBITDA; pro forma acquisitions
2 Before special items

Increased number of employees
As of December 31, 2017, the number of employees increased by 17% to 273,249 (Dec. 31, 2016: 232,873).


Business Segments


Fresenius Medical Care

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of December 31, 2017, Fresenius Medical Care was treating 320,960 patients in 3,752 dialysis clinics. Along with its core business, the company focuses on expanding the range of medical services in the field of Care Coordination.

  • 9% sales growth in constant currency, 7% adjusted net income growth in constant currency3,4
  • 13% operating cash flow growth
  • 2018 outlook: ~8% sales growth5 in constant currency and 13 to 15% net income growth3,6 in constant currency expected

Sales1 increased by 7% (9% in constant currency) to €17,784 million (2016: €16,570 million). Organic sales growth was 7%. Acquisitions and divestitures increased sales by net 2%. Currency translation effects reduced sales by 2%. In Q4/2017, sales of €4,429 million (Q4/2016: €4,417 million) were on the prior-year level (increased by 8% in constant currency).

Health Care services sales (dialysis services and care coordination) increased by 8% (10% in constant currency) to €14,532 million (2016: €13,505 million). Dialysis product sales increased by 6% (7% in constant currency) to €3,252 million (2016: €3,064 million).

In North America, sales increased by 7% to €12,879 million (2016: €12,030 million). Health Care services sales grew by 7% to €12,036 million (2016: €11,214 million). Dialysis product sales increased by 3% to €843 million (2016: €816 million).

Sales outside North America increased by 8% (9% in constant currency) to €4,890 million (2016: €4,527 million). Health Care services sales increased by 9% (11% in constant currency) to €2,496 million (2016: €2,292 million). Dialysis product sales increased by 6% (7% in constant currency) to €2,315 million (2016: €2,185 million).

1Excluding agreement with the United States Depatment of Veterans Affairs and Justice (VA agreement): €17,689 million
2Before natural disaster costs, VA agreement and FCPA provision
3Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
4Before book gain from U.S. tax reform, natural disaster costs, VA agreement and FCPA provision
5Reported sales 2017 of €17,784 million, adjusted for IFRS 15 (€486 million)
6Base 2017: €1,280 million; 2018 including recurring benefits from U.S. tax reform of €140 million to €160 million

EBIT decreased by -2% (0% in constant currency) to €2,362 million (2016: €2,409 million). Adjusted EBIT1 increased by 4% (5% in constant currency) to €2,493 million (2016: €2,409 million), mainly due to the strong business performance in North America and in Asia-Pacific. The adjusted EBIT1 margin was 14.1% (2016: 14.5%). In Q4/2017, EBIT decreased by -29% (-22% in constant currency) to €519 million (2016: €730 million). In Q4/2017, adjusted EBIT1 of €726 million (Q4/2016: €730 million) was slighty below the prior-year level (increased by 6% in constant currency). The adjusted EBIT margin1 was 16.4% (Q4/2016: 16.5%).

Net income2 increased by 12% (14% in constant currency) to €1,280 million (2016: €1,144 million). Consistent with the original scope of guidance, i.e. excluding the effects of the VA agreement, natural disaster costs, the book gain from the US tax reform and the FCPA provision, net income2 increased by 7% in constant currency. In Q4/2017, net income2 increased by 8% (increased 16% in constant currency) to €394 million (Q4/2016: €363 million). Excluding the effects of the VA agreement, natural disaster costs, the book gain from the US tax reform and the FCPA provision, net income2 increased by 6% in constant currency.

Operating cash flow increased by 13% to €2,192 million (2016: €1,932 million). The cash flow margin was 12.3% (2016: 11.7%).

For 2018, Fresenius Medical Care expects sales to grow by ~8%3 in constant currency. The 2018 guidance is based on 2017 sales adjusted for the effect of the IFRS 15 implementation. Net income2 is expected to increase by 13% to 15%4 in constant currency in 2018, including recurring benefits from U.S tax reform of €140 million to €160 million.

1Before natural disaster costs, effects of VA agreement and FCPA provision
2Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
3Reported sales 2017 of €17,784 million, adjusted for effect from IFRS 15 (€486 million)
4Base 2017: €1,280 million

For further information, please see Fresenius Medical Care’s Press Release at www.freseniusmedicalcare.com.

Fresenius Kabi
Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, we are developing products with a focus on oncology and autoimmune diseases.

  • 7% organic sales growth, 8% EBIT2 growth in constant currency
  • Operating cash flow at all-time high
  • 2018 outlook: 4% to 7% organic sales growth and -3% to -6% EBIT growth5 in constant currency expected (~2% to 5%6 excl. biosimilars expenses)

1Before special items
2Consistent with scope of original guidance: before acquisition-related expenses and expenditures for further development of biosimilars business
3Net income attributable to shareholders of Fresenius SE & Co. KGaA
4Consistent with scope of original guidance: before acquisition-related expenses, expenditures for further development of biosimilars business and book gain from U.S. tax reform
5Base 2017: €1,177 million; 2018 before special items (before acquisition-related expenses), including expenditures for further development of biosimilars business (€60 million in FY/17 and expected expenditures of ~€160 million in FY/18)
6Base: 2017: €1,237 million; 2018 before special items (before acquisition-related expenses)

Sales increased by 6% (7% in constant currency) to €6,358 million (2016: €6,007 million). Organic sales growth was 7%. Negative currency translation effects (-1%) were mainly related to the devaluation of the US dollar and the Chinese yuan against the Euro. In Q4/2017, sales increased by 3% (8% in constant currency) to €1,594 million (Q4/2016: €1,550 million). Organic sales growth was 8%.

Sales in Europe grew by 4% (organic growth: 5%) to €2,214 million (2016: €2,135 million). In Q4/2017, sales increased by 2% (3% organic) to €579 million (Q4/2016: €566 million).

Sales in North America increased by 6% (8% organic) to €2,290 million (2016: €2,170 million). In Q4/2017, sales increased by 2% (11% organic) to €554 million (Q4/2016: €542 million).

Sales in Asia-Pacific increased by 8% (11% organic) to €1,196 million (2016: €1,108 million). In Q4/2017, sales increased by 5% (11% organic) to €302 million (Q4/2016: €287 million). Sales in Latin America/Africa increased by 11% (10% organic) to €658 million (2016: €594 million). In Q4/2017, sales increased by 3% (10% organic) to €159 million (Q4/2016: €155 million).

Adjusted EBIT1 increased by 6% (8% in constant currency) to €1,237 million (2016: €1,171 million). The adjusted EBIT margin1 was 19.5% (2016: 19.5%). In Q4/2017, adjusted EBIT1 increased by 3% (9% in constant currency) to €318 million (Q4/2016: €308 million). The adjusted EBIT margin1 was 19.9% (Q4/2016: 19.9%).

EBIT before special items increased by 1% (3% in constant currency) to €1,177 million (2016: €1,171 million). The EBIT margin before special items was 18.5% (2016: 19.5%). In Q4/2017, EBIT before special items decreased by -12% ( 6% in constant currency) to €272 million (Q4/2016: €308 million). The EBIT margin before special items decreased to 17.1% (Q4/2016: 19.9%) due to expenditures for the further development of biosimilars business.

Adjusted net income2,3 increased by 10% (13% in constant currency) to €745 million (2016: €675 million). In Q4/2017, adjusted net income2,3 increased by 4% (10% in constant currency) to €191 million (Q4/2016: €184 million).
Operating cash flow reached an all-time high of €1,010 million (2016: €1,004 million). The cash flow margin was 15.9% (2016: 16.7%).

For 2018, Fresenius Kabi expects organic sales growth of 4% to 7% and EBIT growth in constant currency of -3% to -6%4. Excluding expenditures for the further development of the biosimilars business EBIT is expected to grow by ~2% to 5%5 in constant currency.

1Consistent with scope of original guidance: before acquisition-related expenses and expenditures for further development of biosimilars business
2Net income attributable to shareholders of Fresenius SE & Co. KGaA
3Consistent with scope of original guidance: before acquisition-related expenses, expenditures for further development of biosimilars business and book gain from U.S. tax reform
4Base 2017: €1,177 million; 2018 before special items (before acquisition-related expenses), including expenditures for further development of biosimilars business (€60 million in FY/17 and expected expenditures of ~€160 million in FY/18)
5Base: 2017: €1,237 million; 2018 before special items (before acquisition-related expenses)

Fresenius Helios
Fresenius Helios is Europe's leading private hospital operator. The company comprises Helios Germany and Helios Spain (Quirónsalud). Helios Germany operates 111 hospitals, thereof 88 acute care clinics and 23 post-acute care clinics, and treats more than 5.3 million patients annually. Quirónsalud operates 45 hospitals, 55 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 11.6 million patients per year.

  • 4% organic sales growth
  • 54% EBIT increase (6% excluding Quirónsalud)
  • 2018 outlook: 3% to 6% organic sales growth and EBIT growth of 7% to 10% expected

Fresenius Helios increased sales by 48% to €8,668 million (2016: €5,843 million). Organic sales growth was 4%. Acquisitions, mainly Quirónsalud, increased sales by 44%. In Q4/2017, sales increased by 54% to €2,246 million (Q4/2016: €1,461 million), organic sales growth was 3%.

Sales of Helios Germany increased by 4% (4% organic) to €6,074 million (2016: €5,843 million). In Q4/2017, sales increased by 3% (3% organic) to €1,512 million (Q4/2016: €1,461 million). Helios Spain (Quirónsalud) has been consolidated since February 1, 2017 and generated sales of €2,594 million (thereof €734 million in Q4/2017).

Fresenius Helios grew EBIT by 54% to €1,052 million (2016: €683 million). The EBIT margin increased to 12.1% (2016: 11.7%). In Q4/2017, EBIT increased by 61% to €283 million (Q4/2016: €176 million). The EBIT margin increased to 12.6% (Q4/2016: 12.0%).
EBIT of Helios Germany increased by 6% to €725 million (2016: €683 million) with a margin of 11.9% (2016: 11.7%). In Q4/2017, EBIT of Helios Germany was on the prior-year level with €176 million (Q4/2016: €176 million). The margin was 11.6% (2016: 12.0%).
EBIT of Helios Spain was €327 million (thereof €107 million in Q4/2017) with a margin of 12.6% (Q4/2017: 14.6%).

Net income1 increased by 34% to €728 million (2016: €544 million). In Q4/2017, net income1 increased by 42% to €202 million (Q4/2016: €142 million).

Operating cash flow increased by 18% to €733 million (2016: €622 million) driven by the first-time consolidation of Quirónsalud and an excellent operating result. The margin was 8.5% (2016: 10.6%).

For 2018, Fresenius Helios expects organic sales growth of 3% to 6% and EBIT growth of 7% to 10%.

1Net income attributable to shareholders of Fresenius SE & Co. KGaA

Fresenius Vamed
Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

  • 6% organic sales growth, 10% EBIT growth
  • Order intake of €1,096 million at all-time high
  • 2018 outlook: 5% to 10% organic sales growth and 5% to 10% EBIT growth expected

Sales increased by 6% (6% in constant currency) to €1,228 million (2016: €1,160 million). Organic sales growth was 6%. Sales in the project business increased by 2% to €606 million (2016: €594 million). Sales in the service business grew by 10% to €622 million (2016: €566 million). In Q4/2017, sales increased by 14% to €480 million (Q4/2016: €420 million). Organic sales growth was 14%.

EBIT grew by 10% to €76 million (2016: €69 million). The EBIT margin increased to 6.2% (2016: 5.9%). In Q4/2017, EBIT increased by 16% to €44 million (Q4/2016: €38 million). The EBIT margin increased to 9.2% (2016: 9.0%).

Net income1 grew by 11% to €50 million (2016: €45 million). In Q4/2017, net income1 increased by 21% to €29 million (Q4/2016: €24 million).

Order intake increased to €1,096 million (2016: €1,017 million), reaching an all-time high. As of December 31, 2017, order backlog was €2,147 million (Dec. 31, 2016: €1,961 million).

For 2018, Fresenius Vamed expects organic sales growth in the range of 5% to 10% and EBIT growth of 5% to 10%.

1Net income attributable to shareholders of VAMED AG

Press Conference
As part of the publication of the results for fiscal year 2017, a press conference will be held on February 27, 2018 at 10 a.m. CET. You are cordially invited to follow the press conference in a live broadcast over the Internet at www.fresenius.com/media-calendar. Following the press conference, a replay will be available on our website.

For additional information on the performance indicators used please refer to our website www.fresenius.com/alternative-performance-measures.
For a detailed overview of special items and adjustments, please see the reconciliation tables in the pdf file on page 18-19.